General MedicationsORALStandard

KAZANO

ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE

Standard Dose

EQ 12.5MG BASE;500MG

Max Dose

Refer to approved labeling

Primary Use

Review priority: STANDARD Marketing status: Prescription

Summary

Approval overview KAZANO is listed in Drugs@FDA under application 203414 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 12.5MG BASE;500MG Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2023-07-27 00:00:00.

Structured Monograph

Clinical summary

Approval overview KAZANO is listed in Drugs@FDA under application 203414 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 12.5MG BASE;500MG Sponsor TAKEDA PHARMS USA Submission history Latest submission status date: 2023-07-27 00:00:00. Submission type: SUPPL.

Monitoring

• Marketing status: Prescription
• Review priority: STANDARD

Interaction Notes

No interaction notes stored yet.